Statin use is not associated with prostate cancer risk in men regularly screened for the malignancy, according to investigators.
Elizabeth A. Platz, ScD, MPH, of Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues studied 9,457 men aged 55 years or older who were enrolled in the Prostate Cancer Prevention Trial. Over seven years of follow-up, use of a statin was not associated with PCa risk overall or the risk of lower- or higher-grade PCa, Dr. Platz’s group reported online ahead of print in The Journal of Urology.
“These prospective results do not support the hypothesis that statin drugs protect against prostate cancer in the setting of regular prostate cancer screening,” the authors concluded.
Previous studies have found that men who use statins are at lower risk of aggressive PCa.